Dietary supplementation with cranberry concentrate tablets may increase the risk of nephrolithiasis

Martha Kennedy Terris, Muta M. Issa, J. Ronald Tacker

Research output: Contribution to journalArticle

89 Citations (Scopus)

Abstract

Objectives. Cranberry juice has been recommended for patients with recurrent urinary tract infections. However, cranberry juice has a moderately high concentration of oxalate, a common component of kidney stones, and should be limited in patients with a history of nephrolithiasis. Cranberry concentrate tablets are currently available at nutrition stores and are sold as promoters of urinary tract health. After one of our patients with a distant history of calcium oxalate nephrolithiasis developed recurrent stones following self-administration of cranberry concentrate tablets, we sought to investigate the potential lithogenic properties of cranberry supplements. Methods. Five healthy volunteers on a normal diet provided 24-hour urine collection for pH, volume, creatinine, oxalate, calcium, phosphate, uric acid, sodium, citrate, magnesium, and potassium. Cranberry tablets were administered to these volunteers at the manufacturer's recommended dosage for 7 days. On the seventh day, a second 24-hour urine collection was obtained. Results. The urinary oxalate levels in the volunteers significantly increased (P = 0.01) by an average of 43.4% while receiving cranberry tablets. The excretion of potential lithogenic ions calcium, phosphate, and sodium also increased. However, inhibitors of stone formation, magnesium and potassium, rose as well. Conclusions. Cranberry concentrate tablets are marketed for urinary tract ailments. Physicians and manufacturers of cranberry products should make an effort to educate patients at risk for nephrolithiasis against ingestion of these dietary supplements.

Original languageEnglish (US)
Pages (from-to)26-29
Number of pages4
JournalUrology
Volume57
Issue number1
DOIs
StatePublished - Feb 3 2001

Fingerprint

Vaccinium macrocarpon
Nephrolithiasis
Dietary Supplements
Tablets
Oxalates
Urine Specimen Collection
Urinary Tract
Magnesium
Volunteers
Potassium
Kidney Calculi
Self Administration
Uric Acid
Urinary Tract Infections
Creatinine
Healthy Volunteers
Eating
Ions
Diet
Physicians

ASJC Scopus subject areas

  • Urology

Cite this

Dietary supplementation with cranberry concentrate tablets may increase the risk of nephrolithiasis. / Terris, Martha Kennedy; Issa, Muta M.; Tacker, J. Ronald.

In: Urology, Vol. 57, No. 1, 03.02.2001, p. 26-29.

Research output: Contribution to journalArticle

@article{9d256be06e9e4be68fca0c16ffa1a5b2,
title = "Dietary supplementation with cranberry concentrate tablets may increase the risk of nephrolithiasis",
abstract = "Objectives. Cranberry juice has been recommended for patients with recurrent urinary tract infections. However, cranberry juice has a moderately high concentration of oxalate, a common component of kidney stones, and should be limited in patients with a history of nephrolithiasis. Cranberry concentrate tablets are currently available at nutrition stores and are sold as promoters of urinary tract health. After one of our patients with a distant history of calcium oxalate nephrolithiasis developed recurrent stones following self-administration of cranberry concentrate tablets, we sought to investigate the potential lithogenic properties of cranberry supplements. Methods. Five healthy volunteers on a normal diet provided 24-hour urine collection for pH, volume, creatinine, oxalate, calcium, phosphate, uric acid, sodium, citrate, magnesium, and potassium. Cranberry tablets were administered to these volunteers at the manufacturer's recommended dosage for 7 days. On the seventh day, a second 24-hour urine collection was obtained. Results. The urinary oxalate levels in the volunteers significantly increased (P = 0.01) by an average of 43.4{\%} while receiving cranberry tablets. The excretion of potential lithogenic ions calcium, phosphate, and sodium also increased. However, inhibitors of stone formation, magnesium and potassium, rose as well. Conclusions. Cranberry concentrate tablets are marketed for urinary tract ailments. Physicians and manufacturers of cranberry products should make an effort to educate patients at risk for nephrolithiasis against ingestion of these dietary supplements.",
author = "Terris, {Martha Kennedy} and Issa, {Muta M.} and Tacker, {J. Ronald}",
year = "2001",
month = "2",
day = "3",
doi = "10.1016/S0090-4295(00)00884-0",
language = "English (US)",
volume = "57",
pages = "26--29",
journal = "Urology",
issn = "0090-4295",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Dietary supplementation with cranberry concentrate tablets may increase the risk of nephrolithiasis

AU - Terris, Martha Kennedy

AU - Issa, Muta M.

AU - Tacker, J. Ronald

PY - 2001/2/3

Y1 - 2001/2/3

N2 - Objectives. Cranberry juice has been recommended for patients with recurrent urinary tract infections. However, cranberry juice has a moderately high concentration of oxalate, a common component of kidney stones, and should be limited in patients with a history of nephrolithiasis. Cranberry concentrate tablets are currently available at nutrition stores and are sold as promoters of urinary tract health. After one of our patients with a distant history of calcium oxalate nephrolithiasis developed recurrent stones following self-administration of cranberry concentrate tablets, we sought to investigate the potential lithogenic properties of cranberry supplements. Methods. Five healthy volunteers on a normal diet provided 24-hour urine collection for pH, volume, creatinine, oxalate, calcium, phosphate, uric acid, sodium, citrate, magnesium, and potassium. Cranberry tablets were administered to these volunteers at the manufacturer's recommended dosage for 7 days. On the seventh day, a second 24-hour urine collection was obtained. Results. The urinary oxalate levels in the volunteers significantly increased (P = 0.01) by an average of 43.4% while receiving cranberry tablets. The excretion of potential lithogenic ions calcium, phosphate, and sodium also increased. However, inhibitors of stone formation, magnesium and potassium, rose as well. Conclusions. Cranberry concentrate tablets are marketed for urinary tract ailments. Physicians and manufacturers of cranberry products should make an effort to educate patients at risk for nephrolithiasis against ingestion of these dietary supplements.

AB - Objectives. Cranberry juice has been recommended for patients with recurrent urinary tract infections. However, cranberry juice has a moderately high concentration of oxalate, a common component of kidney stones, and should be limited in patients with a history of nephrolithiasis. Cranberry concentrate tablets are currently available at nutrition stores and are sold as promoters of urinary tract health. After one of our patients with a distant history of calcium oxalate nephrolithiasis developed recurrent stones following self-administration of cranberry concentrate tablets, we sought to investigate the potential lithogenic properties of cranberry supplements. Methods. Five healthy volunteers on a normal diet provided 24-hour urine collection for pH, volume, creatinine, oxalate, calcium, phosphate, uric acid, sodium, citrate, magnesium, and potassium. Cranberry tablets were administered to these volunteers at the manufacturer's recommended dosage for 7 days. On the seventh day, a second 24-hour urine collection was obtained. Results. The urinary oxalate levels in the volunteers significantly increased (P = 0.01) by an average of 43.4% while receiving cranberry tablets. The excretion of potential lithogenic ions calcium, phosphate, and sodium also increased. However, inhibitors of stone formation, magnesium and potassium, rose as well. Conclusions. Cranberry concentrate tablets are marketed for urinary tract ailments. Physicians and manufacturers of cranberry products should make an effort to educate patients at risk for nephrolithiasis against ingestion of these dietary supplements.

UR - http://www.scopus.com/inward/record.url?scp=0035148122&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035148122&partnerID=8YFLogxK

U2 - 10.1016/S0090-4295(00)00884-0

DO - 10.1016/S0090-4295(00)00884-0

M3 - Article

C2 - 11164137

AN - SCOPUS:0035148122

VL - 57

SP - 26

EP - 29

JO - Urology

JF - Urology

SN - 0090-4295

IS - 1

ER -